CSI Market
Sign In | Register

Dicerna Pharmaceuticals Inc (DRNA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access DRNA quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Dicerna Pharmaceuticals Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2020)
12 Months 		(Dec 31 2019) (Dec 31 2018) (Dec 31 2017) (Dec 31 2016)
Operating Activities
Income-112.75
Depreciation & amortization2.22
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation38.91
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease Research And License Receivable-
Non Cash Litigation Expense-
Increase Decrease In Litigation Settlement Payable-
Operating Lease Expense8.10
Noncash Litigation Expense-
Increase Decrease In Lease Liabilities-10.42
Change In Fair Value Of Derivative Liability1.28
Increase Decrease In Contract With Customer Liability-
Income taxes-0.46
Losses/ -gains on Investments net0.00
Accounts Receivable172.38
Increase (Decrease) in Accounts Payable2.21
Accrued Expense0.00
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-12.51
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities86.16
Discontinued operations0.00
Net Cash flow from Operating Activities175.11
Investing Activities
Capital Expenditures-11.75
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities655.00
Payments to Acquire Held-to-maturity Securities-902.13
Real Estate Investments0.00
Changes In Assets Held In Restriction-
Increase (Decrease) in Restricted Cash and Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.02
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-258.86
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock59.57
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-190.74
Payments For Redeemable Convertible Preferred Stock Issuance Costs-
Preferred Stock Dividends And Other Adjustments-
Payments Of Redeemable Convertible Preferred Stock Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents156.71
Right Of Use Asset Obtained In Exchange For Operating Lease Liability32.37
Capital Expenditures Incurred But Not Yet Paid1.61
Payments Of Stock Issuance Costs Excluding Brokerage Commissions-0.10
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities59.42
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow163.37
Total Cash Flow-24.33
4 historic quarters locked

Sign in to unlock the full Dicerna Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About DRNA Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License